Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Fast, Cheap, and Sometimes Even Good | Main | Memorial »

August 10, 2004

Solid Citizens

Email This Entry

Posted by Derek

I took the day off yesterday, but this morning it's back to the lab. I didn't leave any chemistry going in my hood, so there should be no surprises there, unless one of the things I've left sitting around took the opportunity to crystallize.

Just about every drug candidate we make should have one or more crystalline forms - we don't usually bother testing molecules that are too small to be solids at room temperature. But that doesn't mean that they all crystallize easily. Some things really need coaxing. If there's the least bit of water or solvent left in them, they sit around as thick oils, gums, or syrups.

Some of them will decide, after a few weeks, to finally start growing some crystals. Perhaps some of the volatile impurities finally evaporate, or possibly the molecules just finally banged into each other the right way and decided to set up housekeeping in the solid state. And you can't rule out the beneficial effects of lab dust for starting things off, either. There are all kinds of legends about labs in the old days that cleaned things up so well that their stock-in-trade compounds wouldn't crystallize any more.

I had a compound from my first year of graduate school, a light yellow syrup that I kept around my whole time there, that finally decided to start growing thick faceted crystalline plates in my (and its) fourth year. This just might have had something to do with most the compounds I made being carbohydrate derivatives, which have a fairly accurate reputation for not crystallized except at gunpoint.

The thicker the syrup, the slower these things happen, as you'd figure. Real crystallizations out of solution, by contrast, can be pretty dramatic - a sudden whoomphing snowstorm in the flask. Do it too fast, though, and impurities will be entrained and come down with your solid. The ideal is a noticable, steady growth, the sort of thing you leave overnight and come back for.

For the most part, we don't care too much during the synthesis if things are solids or not. It makes compounds easier to transfer and handle if they are, but you can always dissolve up a goo or sludge in some solvent. But for final drug candidates, a reproducible crystalline form is a good thing to have. It's close to crucil if you dose as a suspension. You'll get into trouble if you keep dosing poorly characterized solids, which might contain various amounts of various crystal forms along with amorphous material, all of which dissolve at different rates.

Comments (2) + TrackBacks (0) | Category: Life in the Drug Labs


COMMENTS

1. Greg Hlatky on August 10, 2004 7:23 AM writes...

Why do you always write about topics I'm just getting ready to write about? This is starting to get annoying.

Permalink to Comment

2. Derek Lowe on August 10, 2004 10:38 AM writes...

As I told Greg in an e-mail, I'm clearly going to have to switch to a thicker brand of foil for my hat, in order to not pick up his psychic vibrations.

Now, why I'm picking up signals from an inorganic/polymer chemist instead of someone from my own end of the science, I don't know. . .

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Molecular Printing of Drug Molecules. Say What?
Pfizer Walks Again By Night
Gitcher SF5 Groups Right Here
Changing A Broken Science System
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi